Industry News

15 April 2026

Johnson & Johnson Highlights Favorable 12-Month Interim Results for the VARIPULSE Platform at EHRA 2026

Johnson & Johnson today announced favorable 12-month interim effectiveness and safety results from VARIPURE, the largest prospective post-market follow-up study evaluating first-time pulsed field ablation (PFA) using the VARIPULSE Platform. The data were presented at the PFA Summit during the 2026 European Heart Rhythm Association (EHRA) Annual Meeting in Paris and simultaneously published in Europace.

10 April 2026

Lupin announces approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the USA

Lupin Limited announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg.

10 April 2026

Amgen announced results from a Phase 3 trial of TEPEZZA

Amgen announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid Eye Disease

27 March 2026

Novo Nordisk : Awiqli® approved in the USA

Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycaemic control (blood sugar) in adults living with type 2 diabetes.

18 March 2026

Zydus Lifesciences & Torrent Pharmaceuticals Partner to Co-Market Semaglutide in India

Zydus Lifesciences Limited an innovation-led global life-sciences company and Torrent Pharmaceuticals Limited a specialty-focused global pharmaceutical company, have entered into a Licensing and Supply Agreement to co-market Semaglutide Injection in the Indian market.

5 March 2026

Moderna Settles Vaccine Patent Dispute with 950 Million USD Deal

Biotechnology company Moderna has announced a major settlement to resolve global patent litigation with Arbutus Biopharma Corporation and Genevant Sciences GmbH over technology used in its mRNA vaccines. The agreement settles all ongoing lawsuits worldwide related to the companies’ disputes.

5 March 2026

Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease

The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to rilzabrutinib, a novel, oral, reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor, for IgG4-related disease (IgG4-RD).

5 March 2026

US FDA Approves Glenmark’s Generic Fluticasone Propionate Inhaler for Asthma Treatment

Glenmark Specialty SA has received final approval from the U.S. Food and Drug Administration for Fluticasone Propionate Inhalation Aerosol USP

2 March 2026

Novo Nordisk Announces Euro 432 Million Expansion of Athlone Manufacturing Facility

March 2, 2026: In a strategic move to support global demand for oral GLP-1 therapies, Novo Nordisk has revealed plans to invest 432 million euro (approximately DKK 3.2 billion) in expanding its manufacturing operations in Athlone, Ireland.

The investment will significantly increase capacity at Novo Nordisk’s tablet production facility located in Monksland, Athlone, with upgrades aimed at broadening the company’s ability to produce current and future oral GLP-1 medicines. These medicines, used for treating conditions such as diabetes and obesity, have seen rising global demand.

28 February 2026

Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy

Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens, the generic equivalent of Saxenda® (liraglutide injection).

Search

Johnson & Johnson Highlights Favorable 12-Month Interim Results for the VARIPULSE Platform at EHRA 2026

RECOMMENDED POSTS

Subscribe with us

Jobs by Category